Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT07263035

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Lakeland Regional Health Systems, Inc. (from the registry)
Registry
  • NCT NCT07263035
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07263035. Randomized; no masking; primary purpose treatment. Start 2026-04-01 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure
Acronym
US-DASH
Condition
Heart Failure
Condition
Heart Failure - NYHA II - IV
Condition
Heart Failure Acute
Condition
Acute Heart Failure (AHF)
Intervention (Drug)
Furosemide intravenous solution
Intervention (Drug)
Furosemide intravenous solution
Intervention (Drug)
Furosemide intravenous solution
Lead sponsor
Lakeland Regional Health Systems, Inc. (class: other)

Record details

Record id
cardio:ct-nct07263035
Content hash
4524c08a7692d376b669ccfc9f84c18c5358c0cb4cf0d22cbda49ec70bb58284